Abstract
To explore the relationship between mutant p53 and Pgp expression, we have examined the levels of both proteins in human colorectal adenocarcinomas. Serial frozen sections of 40 surgical samples were stained with an anti‐Pgp (MRK16) and two different anti‐p53 protein antibodies (Abs), PAb421 and Pabl80l. Nineteen (47.5%) of 40 samples examined were positive for Pgp, and 18 (45%) of 40 were positive for p53. The samples that stained positively with PAb421 also stained positively with Pahl80l. Pgp expression was detected in 13 (76.5%) of 17 samples that were positive for p53 using PAb421 and in 15 (83.3%) of 18 samples that were positive for p53 using Pabl80. Thus, we found that p53 and Pgp were co‐expressed in a significant number of samples (P< 0.002). There was no relationship between Pgp or p53 protein accumulation and histologic grade or stage. The present results demonstrate that Pgp expression is closely associated with p53 protein accumulation in human colorectal cancers. These data provide evidence to support the idea that mutant p53 activates the MDR1 gene in vivo.
Keywords: P‐glycoprotein, p53, Colon cancer, Multidrug resistance, MDR1 gene
Full Text
The Full Text of this article is available as a PDF (589.3 KB).
REFERENCES
- 1. ) Gottesman , M. M. and Pastan , I.Biochemistry of multidrug resistance mediated by the multidrug transporter . Annu. Rev. Biochem. , 62 , 385 – 427 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Weinstein , R. S. , Kuszak , J. R. , Kluskens , L. F. and Coon , J. S.P‐Glycoproteins in pathology: the multidrug resistance gene family in humans . Hum. Pathol. , 21 , 34 – 48 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 3. ) Cordon‐Cardo , C. , O'Brien , J. P. , Boccia , J. , Casals , D. , Bertino , J. R. and Melamed , M. R.Expression of the multidrug resistance gene product (P‐glycoprotein) in human normal and tumor tissues . J. Histochetn, Cytochem. , 38 , 1277 – 1287 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Pastan , I. and Gottesman , M. M.Multiple‐drug resistance in human cancer . N. Engl. J. Med. , 316 , 1388 – 1393 ( 1987. ). [DOI] [PubMed] [Google Scholar]
- 5. ) Greenblatt , M. S. , Bennett , W. P. , Hollstein , M. and Harris , C. C.Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res. , 54 , 4855 – 4878 ( 1994. ). [PubMed] [Google Scholar]
- 6. ) Wahl , A. F. , Donaldson , K. L. , Fairchild , C. , Lee , F. Y. F. , Foster , S. A. , Demers , G. W. and Galloway , D. A.Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis . Nat. Med. , 2 , 72 – 79 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Hawkins , D. S. , Demers , G. W. and Galloway , D. A.Inactivation of p53 enhances sensitivity to multiple chemo‐therapeutic agents . Cancer Res. , 56 , 892 – 898 ( 1996. ). [PubMed] [Google Scholar]
- 8. ) Aas , T. , Børresen , A.‐L. , Geisler , S. , Smith‐Sørensen , B. , Johnsen , H. , Varhaug , J. E. , Akslen , L. A. and Lønning , P. E.Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients . Nat. Med. , 2 , 811 – 814 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Lutzker , S. G. and Levine , A. J.A functionally inactive p 53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation . Nat. Med. , 2 , 804 – 810 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Chin , K.‐V. , Ueda , K. , Pastan , I. and Gottesman , M. M.Modulation of activity of the promoter of the human MDR1 gene by ras and p53 . Science , 255 , 459 – 462 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Dittmer , D. , Pati , S. , Zambetti , G. , Chu , S. , Teresky , A. K. , Moore , M. , Finlay , C. and Levine , A. J.Gain of function mutations in p53 . Nat. Genet. , 4 , 42 – 46 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Zastawny , R. L. , Salvino , R. , Chen , J. , Benchimol , S. and Ling , V.The core promoter region of the P‐glycoprotein gene is sufficient to confer differential responsiveness to wild‐type and mutant p53 . Oncogene , 8 , 1529 – 1535 ( 1993. ). [PubMed] [Google Scholar]
- 13. ) Nguyen , K. T. , Liu , B. , Ueda , K. , Gottesman , M. M. , Pastan , I. and Chin , K. V.Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants . Oncol. Res. , 6 , 71 – 77 ( 1994. ). [PubMed] [Google Scholar]
- 14. ) Rouby , S. El. , Thomas , A. , Costin , D. , Rosenberg , C. R. , Potmesil , M. , Silber , R. and Newcomb , E. W.p53 gene mutation in B‐cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/ MDR3 gene expression . Blood , 82 , 3452 – 3459 ( 1993. ). [PubMed] [Google Scholar]
- 15. ) Preudhomme , C. , Lepelley , P. , Vachee , A. , Soenen , V. , Quesnel , B. , Cosson , A. and Fenaux , P.Relationship between p53 gene mutations and multidrug resistance (mdrl) gene expression in myelodysplastic syndromes . Leukemia , 7 , 1888 – 1890 ( 1993. ). [PubMed] [Google Scholar]
- 16. ) Renninson , J. , Baker , B. W. , McGown , A. T. , Murphy , D. , Norton , J. D. , Fox , B. W. and Growther , D.Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features . Br. J. Cancer , 69 , 609 – 612 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. ) Schneider , J. , Rubio , M. , Barbazan , M. , Rodriguez‐Escudero , F. J. , Seizinger , B. R. and Castresana , J. S.P‐glycoprotein, HER‐2/neu, and mutant p53 expression in human gynecologic tumors . J. Natl. Cancer Inst. , 86 , 850 – 855 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 18. ) Wallner , J. , Gisslinger , H. , Gisslinger , B. , Gsur , A. , Götzl , M. , Zöchbauer , S. and Pirker , R.MDR1 gene expression in chronic lymphocytic leukemia . Leuk. Lymphoma , 13 , 333 – 338 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 19. ) Charpin , C. , Vielh , P. , Duffaud , F. , Devictor , B. , Andrac , L. , Lavaut , M. N. , Allasia , C. , Horschowski , N. and Piana , L.Quantitative immunocytochemical assays of P‐glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators . J. Natl. Cancer Inst. , 86 , 1539 – 1545 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 20. ) Baker , S. J. , Preisinger , A. C. , Jessup , J. M. , Paraskeva , C. , Markowitz , S. , Willson , J. K. V. , Hamilton , S. and Vogelstein , B.p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorgenesis . Cancer Res. , 50 , 7717 – 7722 ( 1990. ). [PubMed] [Google Scholar]
- 21. ) Weinstein , R. S. , Jakate , S. M. , Dominguez , J. M. , Lebovitz , M. D. , Koukoulis , G. K. , Kuszak , J. R. , Klusens , L. F. , Grogan , T. M. , Saclarides , T. J. , Roninson , I. B. and Coon , J. S.Relationship of the expression of the multidrug resistance gene product (P‐glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis . Cancer Res. , 51 , 2720 – 2726 ( 1991. ). [PubMed] [Google Scholar]
- 22. ) Hall , P. A. and Lane , D. P.p53 in tumour pathology: can we trust immunohistochemistry ? – revisited . J. Pathol , 172 , 1 – 4 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 23. ) Shi , S.‐R. , Chaiwun , B. , Young , L. , Cote , R. J. and Taylor , C. R.Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin‐fixed paraffin sections . J. Histochem. Cytochem. , 41 , 1599 – 1604 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 24. ) Baas , I. O. , Mulder , J. R. , Offerhaus , G. J. A. , Vogelstein , B. and Hamilton , S. R.An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms . J. Pathol. , 172 , 5 – 12 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 25. ) Purdie , C. A. , O'Grady , J. , Piris , J. , Wyllie , A. H. and Bird , C. C.p53 expression in colorectal tumors . Am. J. Pathol , 138 , 807 – 813 ( 1991. ). [PMC free article] [PubMed] [Google Scholar]
- 26. ) van den Berg , F. M. , Tigges , A. J. , Schipper , M. E. L , Den Hartog‐Jager , F. C. A. , Kroes , W. G. M. and Walboomers , J. M. M.Expression of the nuclear oncogene p53 in colon tumors . J. Pathol , 157 , 193 – 199 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 27. ) Pirker , R. , Wallner , J. , Gsur , A. , Götzl , M. , Zöchbauer , S. , Scheithauer , W. and Depisch , D.MDR1 gene expression in primary colorectal carcinomas . Br. J. Cancer , 68 , 691 – 694 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. ) Goldsmith , M. E. , Gudas , J. M. , Schneider , E. and Cowan , K. H.Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53‐negative cell line . J. Biol. Chem. , 270 , 1894 – 1898 ( 1995. ). [PubMed] [Google Scholar]
- 29. ) Hollstein , M. , Sidransky , D. , Vogelstein , B. and Harris , C. C.p53 mutations in human cancers . Science , 253 , 49 – 53 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 30. ) Kern , S. E. , Kinzler , K. W. , Bruskin , A. , Jarosz , D. , Friedman , P. , Prives , C. and Vogelstein , B.Identification of p53 as a sequence‐specific DNA‐binding protein . Science , 252 , 1708 – 1710 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 31. ) Pietenpol , J. A. and Vogelstein , B.No room at the p53 inn . Nature , 365 , 17 – 18 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 32. ) El‐Deiry , W. S. , Kern , S. E. , Pietenpol , J. A. , Kinzler , K. W. and Vogelstein , B.Definition of a consensus binding site for p53 . Nat. Genet. , 1 , 45 – 49 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 33. ) Bradley , G. , Sharma , R. , Rajalakshimi , S. and Ling , V.P‐glycoprotein expression during tumor progression in the rat liver . Cancer Res. , 52 , 5154 – 5161 ( 1992. ). [PubMed] [Google Scholar]
- 34. ) Benchimol , S. and Ling , V.P‐glycoprotein and tumor progression . J. Natl. Cancer Inst. , 86 , 814 – 816 ( 1994. ). [DOI] [PubMed] [Google Scholar]